Search > Results
You searched for: EV230005 (EV-TRACK ID)
Showing 1 - 4 of 4
Showing 1 - 4 of 4
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV230005 | 1/4 | Homo sapiens | Serum | (d)(U)C | Dobra G | 2023 | 55% | |
Study summaryFull title
All authors
Dobra G, Gyukity-Sebestyén E, Bukva M, Harmati M, Nagy V, Szabó Z, Pankotai T, Klekner Á, Buzás K
Journal
Cancers (Basel)
Abstract
Matrix metalloproteinase-9 (MMP-9) degrades the extracellular matrix, contributes to tumour cell inv (show more...)
EV-METRIC
55% (91st percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: Alix/ CD5L/ MMP-9
non-EV: calnexin Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 10,000 g and 50,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: rotor type
T-1270
Pelleting: speed (g)
110000
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Detected EV-associated proteins
Alix/ CD5L
Not detected contaminants
calnexin
ELISA
Detected EV-associated proteins
MMP-9
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
77.3
EV concentration
Yes
Particle yield
particles per milliliter of starting sample: 1.44E+12
EM
EM-type
Transmission-EM
Image type
Close-up
|
||||||||
EV230005 | 2/4 | Homo sapiens | Serum | (d)(U)C | Dobra G | 2023 | 44% | |
Study summaryFull title
All authors
Dobra G, Gyukity-Sebestyén E, Bukva M, Harmati M, Nagy V, Szabó Z, Pankotai T, Klekner Á, Buzás K
Journal
Cancers (Basel)
Abstract
Matrix metalloproteinase-9 (MMP-9) degrades the extracellular matrix, contributes to tumour cell inv (show more...)
EV-METRIC
44% (86th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Glioblastoma
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: Alix/ CD5L/ MMP-9
non-EV: calnexin Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 10,000 g and 50,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: rotor type
T-1270
Pelleting: speed (g)
110000
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Detected EV-associated proteins
Alix/ CD5L
Not detected contaminants
calnexin
ELISA
Detected EV-associated proteins
MMP-9
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
80.6
EV concentration
Yes
Particle yield
particles per milliliter of starting sample: 2.46E+12
|
||||||||
EV230005 | 3/4 | Homo sapiens | Serum | (d)(U)C | Dobra G | 2023 | 44% | |
Study summaryFull title
All authors
Dobra G, Gyukity-Sebestyén E, Bukva M, Harmati M, Nagy V, Szabó Z, Pankotai T, Klekner Á, Buzás K
Journal
Cancers (Basel)
Abstract
Matrix metalloproteinase-9 (MMP-9) degrades the extracellular matrix, contributes to tumour cell inv (show more...)
EV-METRIC
44% (86th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Brain metastasis originated from non-small cell lung cancer
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: Alix/ CD5L/ MMP-9
non-EV: calnexin Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 10,000 g and 50,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: rotor type
T-1270
Pelleting: speed (g)
110000
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Detected EV-associated proteins
Alix/ CD5L
Not detected contaminants
calnexin
ELISA
Detected EV-associated proteins
MMP-9
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
84.8
EV concentration
Yes
Particle yield
particles per milliliter of starting sample: 1.59E+12
|
||||||||
EV230005 | 4/4 | Homo sapiens | Serum | (d)(U)C | Dobra G | 2023 | 44% | |
Study summaryFull title
All authors
Dobra G, Gyukity-Sebestyén E, Bukva M, Harmati M, Nagy V, Szabó Z, Pankotai T, Klekner Á, Buzás K
Journal
Cancers (Basel)
Abstract
Matrix metalloproteinase-9 (MMP-9) degrades the extracellular matrix, contributes to tumour cell inv (show more...)
EV-METRIC
44% (86th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Meningioma
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: Alix/ CD5L/ MMP-9
non-EV: calnexin Proteomics
yes
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 10,000 g and 50,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: rotor type
T-1270
Pelleting: speed (g)
110000
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Detected EV-associated proteins
Alix/ CD5L
Not detected contaminants
calnexin
ELISA
Detected EV-associated proteins
MMP-9
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
82.7
EV concentration
Yes
Particle yield
particles per milliliter of starting sample: 3.61E+12
|
||||||||
1 - 4 of 4 |
EV-TRACK ID | EV230005 | |||
---|---|---|---|---|
species | Homo sapiens | |||
sample type | Serum | |||
condition | Control condition | Glioblastoma | Brain metastasis originated from non-small cell lung cancer | Meningioma |
separation protocol | dUC | dUC | dUC | dUC |
Exp. nr. | 1 | 2 | 3 | 4 |
EV-METRIC % | 55 | 44 | 44 | 44 |